, related to Figure 1 (A) Exemplary measurement of the size distribution of DOPC and NE liposomes used in Figure 1A and B as determined by light scattering. The mean diameters of the different sized liposome preparations are indicated below. (B) The N-terminus of Nup153 can deform membranes: 3 M Xenopus Nup153 Nterminus (aa 1-149) or the corresponding V50E mutant was incubated with 1 mg/ml Folch Fraction I liposomes (average diameter approx. 70 nm). The samples were analyzed on copper grids by transmission electron microscopy on a FEI Technai spirit 120 kV microscope as in (Vollmer et al., 2012) . Please note the liposome tubulation in the presence of Nup153 N-terminus, which is not induced by Bar: 100 nm.
the membrane binding defective V50E mutant or the buffer control.
(C) EGFP-tagged Nup153 N-terminus localizes to the NE: Images show HeLa cells with lower expression levels of EGFP-tagged Nup153 N-terminus as compared to Figure 1F . DNA was stained with DAPI (blue). Bar: 10 m. Nup153 depleted extracts supplemented with recombinant wild type protein (Nup153) or the membrane-binding mutant (Nup153 V47E). Samples were analyzed by immunofluorescence for the presence of Nup107 and Nup133 (nucleoporins of the Y-complex), Nup155 and Nup53 (nucleoporins of the Nup93-complex) and Nup58 (a central channel nucleoporin). DNA was stained with DAPI (blue). Bar 10 µm. (A) GST-fusions of the RRM domain of Xenopus Nup53 (aa 162-267) (Vollmer et al., 2012) as a control and GST-fusions of the MBD-ycBD and MBD-RanBD constructs as well as the corresponding membrane binding mutants (V50E), were incubated with cytosol from Xenopus egg extracts. Eluates were analyzed by western blotting with antibodies against Nup160, Nup107 and Ran. (B) 3 M of the MBD-ycBD and MBD-RanBD fusion proteins as well as the corresponding membrane binding mutants (V50E) were incubated with fluorescently labeled 70 nm NE liposomes and floated through a sucrose gradient. Top gradient fractions and input materials were analyzed by western blot with the -Nup153 antibody which is directed against the MBD. (C) Silverstaining of the purified Y-complex. The Y-complex was purified from
Xenopus egg extracts using TAP-tagged Nup98 (Walther et al., 2003) . After TEV protease elution the complex was separated on a 5%-12% SDS-PAGE. (A) Size distribution of EGFP-ycBD-BC08 and EGFP-RanBD-BC08 proteo-liposomes used in Figure 5B and D as determined by light scattering. The mean liposome diameter of the two preparations is indicated. (B) The ycBD-BC08 fusion recruits the Y-complex to NPC assembly sites. Nuclei were assembled in Nup153 depleted extracts supplemented with ycBD-BC08 or RanBD-BC08 containing liposomes (the EGFP tag was cleaved before liposome reconstitution to avoid interference with the Alexa-488 labeled Y-complex signal). NPCs are visualized with Alexa-594 labeled WGA (red in overlay) and, the purified labeled Y-complex is shown in green. Bar: 1 µm. (C) The EGFP-RanBD-BC08 and EGFP-ycBD-BC08 fusions translocate to the inner nuclear membrane as determined by a protease protection assay described in (Theerthagiri et al., 2010) . Nuclei were assembled in 60 µl Xenopus egg extracts. After 50 min, i.e. when a closed NE has formed, proteo-liposomes containing the EGFP-RanBD-BC08 or EGFP-ycBD-BC08 fusions were added. At indicated time points after liposome addition, a 10 µl sample was taken, NusA fused TEV protease was added, and protease cleavage was stopped by addition of SDS sample buffer and boiling. Protease protection of the reporter was analyzed by Western blotting. The position of the un-cleaved (EGFP-RanBD-BC08 and EGFP-ycBD-BC08) and the cleaved EGFP reporter are indicated. Quantification of the EGFP signal reveals a half time of inner nuclear membrane transport of 6.7 min and 7.3 min for EGFP-RanBD-BC08 or EGFP-ycBD-BC08, respectively. (D) Quantification of nuclei assembled as in Figure 5D with NPC clustering identified by mAB414 staining (three independent experiments with 100 chromatin substrates each). Please note the rescue of the NPC clustering phenotype by the EGFP-ycBD-BC08 construct probably because in this situation newly formed NPCs are inserted in all areas of the nuclear envelope. (E) Nuclei were assembled for 120 min in mock, Nup153 depleted (ΔNup153) or Nup153 depleted extracts supplemented with recombinant wild type protein (wt) or a Nup153 deletion mutant lacking the Y-complex interaction site (ΔycBD, human Nup153 lacking aa 211-337, see extended experimental procedure section). Samples were analyzed by immunofluorescence with α-Nup153 and mAB414 antibodies. DNA was stained with DAPI (blue). Bar 10 µm (F) NPC numbers in nuclei assembled as in (B) were determined using mAB414 staining (average from 10 nuclei, normalized to the mock control, error bars are SEM). (G) Nuclei were assembled as in (B) and interphasic NPC assembly on more than 100 nuclei was analyzed by dextran influx.
Figure S5, related to Figure 7
GST-fusions of the RRM domain of Xenopus Nup53 (aa 162-267) (Vollmer et al., 2012) as a control, of Xenopus Nup153 (aa-149), the corresponding membrane binding mutant (V50E), or of a Xenopus Nup153 fragment (aa 395-608) that is known to bind Nup50 (Makise et al., 2012) , were incubated with cytosol from Xenopus egg extracts. Where indicated, 10 µM RanQ69L was added to the incubation. Eluates were analyzed by western blotting with antibodies against transportin and importin β. Please note that transportin binding to the Nup153 Nterminal fragment is not affected by the V50E mutation. The Nup153 aa 395-608 fragment binds transportin, consistent with a previous report that mapped a transportin binding site to a partially overlapping Nup153 fragment (aa 440-720) (Shah and Forbes, 1998) Supplemental Movie 1 3D reconstruction (generated with IMARIS) of confocal stacked images of a representative HeLa cell transfected with EGFP-Nup153xl 1-149, as shown in Figure 1F . 
Supplemental Experimental Procedures
DiIC18 (1,1'-Dioctadecyl-3,3,3',3'-Tetramethylindocarbocyanine Perchlorate), DiDC18
(1,1'-Dioctadecyl-3,3,3',3'-Tetramethylindodicarbocyanine Perchlorate), fluorescently labeled dextrans, Alexa dyes and secondary antibodies were obtained from Life Technologies, detergents from EMD, and lipids from Avanti Polar Lipids.
Antibodies Antibodies against Nup107 (Walther et al., 2003) , GP210 (Antonin et al., 2005) , NDC1 (Mansfeld et al., 2006 ), Nup160 (Franz et al, 2007 , Nup53 and LBR (Theerthagiri et al., 2010) and Nup58 have been described. mAB414 (Babco), transportin and Ran (558660 and 610341, BD Bioscience), EGFP (11814460001, Roche), as well as TPR, human lamin A and B2 antibodies (ab58344, ab26300, ab151735 abcam) were purchased. Antibodies for POM121, RTN4, Nup153 and Nup133, were generated against recombinant fragments of the respective proteins (Xenopus POM121 aa 1-314, RTN4 aa 763-1043 and Nup153 aa 1-149, human Nup133 aa 67-514). Antibodies for Nup155, Nup50, importin β, lamin B (expressed as GFP-laminB3, kind gift from Rebecca Heald) are against the Xenopus full-length proteins, Xenopus importin α and BC08 antibodies are a kind gift from Iain Mattaj.
Protein expression and purification Constructs for the Xenopus Nup153 N-terminus (aa 1-149) were generated from synthetic DNA optimized for codon usage in E. coli (Geneart), human full-length constructs from EGFP3-hNup153 (Rabut et al., 2004 ) and the corresponding V50E or V47E mutants by mutagenesis using QuikChange site-directed mutagenesis kit (Agilent). The Nup153 N-terminus (wildtype and V50E mutant) was cloned into a modified pET28a vector with a yeast SUMO solubility tag followed by a TEV site or into a modified pET28a vector with EGFP upstream of Nup153. MBD-ycBD and MBD-RanBD fusions as well as the corresponding membrane binding mutants were generated by insertion of human Nup153 fragments (aa 210-338 or aa 658-890) into the above mentioned constructs of the Xenopus Nup153 N-terminus (wildtype and V50E mutant) in the SUMO containing pET28a vector. The Nup153 mutant lacking the Y-complex binding domain (Nup153 ΔycBD, Figure  S3 ) was generated by cloning sequentially the N-terminal 210 aa of human Nup153 and the C-terminal Nup153 portion starting from aa 338 into the SUMO containing pET28a vector. Both fragments are joined by a GGSKLGGS linker. Proteins were expressed in E. coli and purified using Ni-agarose. His 6 -and SUMOtags were cleaved using TEV protease and proteins were concentrated using VIVASPIN columns (Sartorius) and separated by gelfiltration (Superdex200 10/300 GL or Superdex200 PC 3.2/30, GE Healthcare) in HEPES buffer (20 mM HEPES pH 7.5, 150 mM NaCl, 1mM DTT). SUMO and EGFP were expressed and purified from the corresponding empty vectors. Human Nup133 (aa 67-514) was generated as described (Vollmer et al., 2012) . Y-complex was purified from Xenopus egg extracts using TAP-tagged Nup98 (Walther et al., 2003) and labelled using Alexa Fluor 546 carboxylic acid succinimidyl ester in 200 mM NaHCO 3 pH 8.4. Human RanQ69L was expressed from a modified pET28a vector with a His 6 -GST tag, which was cleaved of using TEV protease. The protein was separated from the tag after dialysis using Ni-agarose and further purified by gelfiltration (Superdex200 10/300 GL). Purified ranQ69L was labelled using Alexa Fluor 546 C5 maleimide in HEPES buffer. Excess dye was removed by gelfiltration (Superdex200 PC 3.2/30).
EGFP-ycBD-BC08 or EGFP-RanBD-BC08 where generated by insertion of human Nup153 fragments (aa 210-338 or aa 658-890) into an BC08 reporter construct (Theerthagiri et al., 2010) between EGFP and BC08. The corresponding constructs were expressed, purified and reconstituted into small unilamellar liposomes (see below).
Transfection experiments
Plasmids encoding the Xenopus Nup153 N-terminus and the corresponding V50E mutant (cloned into a modified pEGFP-C3 vector) were transfected into HeLa cells using Fugene 6 (Roche) following the manufacturer's instructions. After 24 h cells were fixed and analyzed by confocal microscopy. For immunoprecipitations, EGFP3-hNup153 constructs were transfected into HEK293 cells. 24 h post-transfection cells were harvested and lysed in lysis buffer (50 mM TRIS-HCl pH 7.5, 150 mM NaCl, 1 mM EDTA, 10% glycerol, 0.1% Triton X-100 supplemented with protease inhibitors (2 µg/ml leupeptin, 1 µg/ml pepstatin, 2 µg/ml aprotinin, 0.1 mg/ml AEBSF final concentration) for 30 min at 4°C. After centrifugation for 15 min at 15.000 x g the supernatant was immunoprecipitated with GFP-Trap beads (Chromotek) for 2 h, washed 5x with lysis buffer, 2x with lysis buffer supplemented with 500 mM NaCl, 2x with lysis buffer, and 1x with lysis buffer without Triton X-100 and finally eluted with SDS-sample buffer. Eluates and lysed cells (corresponding to 5% of the eluates) were analyzed. For colocalization experiments (Figure 2A ), pEGFP3-Nup153hs or pEGFP3-Nup153hsV47E were co-transfected with mCherry-hLMNB2 (kind gift of Martin Hetzer) or mCherry-Nup62xl using jetPRIME (Polyplus transfection). 24 h after transfection live cells were imaged at 37°C with a confocal microscope LSM780 (Zeiss) equipped with incubation chamber and using an Apochromat 63x/1.40 Oil DIC M27 objective.
GST Pulldown experiments
Fragments used for the GST pulldown experiments were cloned into a modified pET28a vector with GST tag followed by a recognition site for TEV protease and purified via the N-terminal His 6 tag. 60 µl GSH-Sepharose (GE Healthcare) was incubated with 300 µg of the indicated proteins, washed and blocked with 5% BSA in PBS. Beads were incubated with cytosol from Xenopus egg extracts (diluted 1:1 with PBS, and cleared by centrifugation for 30 min at 100,000 rpm in a TLA110 rotor (Beckman Coulter) for 2 h and washed six times with PBS. Bound proteins were eluted by cleavage with TEV protease (0.5 mg/ml) for 1 h at RT and analyzed by SDS-PAGE and Western blotting.
Liposome generation and flotation NE lipid mixture -60 mol% L-α-phosphatidylcholine, 19.8 mol% L-α-phosphatidylethanolamine, 10 mol% L-α-phosphatidylinositol, 5 mol% Cholesterol, 2.5 mol% Sphingomyelin, 2.5 mol% L-α-phosphatidylserine, 0.2 mol% 18:1-12:0 NBD-PE (1-oleoyl-2-{12-[(7-nitro-2-1,3-benzoxadiazol-4-yl)amino]dodecanoyl}-snglycero-3-phosphoethanolamine) or DOPC mixture -99.8 mol% 1,2-dioleoyl-snglycero-3-ethylphosphocholine (DOPC), 0.2 mol% 18:1-12:0 NBD-PE -were dissolved in chloroform to a final concentration of 1 mg/ml. Chloroform was evaporated in a glass vial under a low stream of Argon until an even lipid film formed followed by incubation under vacuum for 1-2 h. Liposomes were formed by gentle addition of HEPES buffer to a final concentration of 5 mg/ml. After 1 h of incubation at 45°C, flask was shaken to dissolve residual lipids. After ten cycles of freeze/thawing liposomes were either snap frozen in liquid nitrogen and stored at -80°C or directly used. Different sized liposomes were formed by passing liposomes sequentially through Nuclepore Track-Etched Membranes (Whatman) with defined pore sizes (400, 100, 30 nm) at 45°C using the Avanti Mini-Extruder until desired size was reached. For 30 nm, liposomes were incubated in a sonication bath for 5 min before final extrusion. To ensure equal concentrations of different sized liposomes, fluorescence intensity was determined after extrusion using a Molecular Imager VersaDoc MP 4000 Imaging System and ImageJ. Concentrations were adjusted by dilution. Liposome sizes were determined by light scattering using the AvidNano W130i with 10 measurements per sample each for 10 sec and analyzed using the iSize software. For liposome flotations proteins (6 µM) were mixed 1:1 with liposomes (5 mg/ml) and incubated for 30 min at 25°C. 75 µl of the protein/liposome mixture was brought to 37% sucrose concentration in a total volume of 150 µl. 1.7 ml 12% sucrose cushion in HEPES buffer was overlaid, followed by 300 µl HEPES buffer on top. Samples were spun for 2 h at 55 000 rpm in a TLS-55 rotor (Beckman) at 25°C. Liposomes containing top layers were collected (450 µ l). Fluorescence intensities of the start protein/liposome mixture and the top fraction were determined. Usual liposome recovery rates are 60%. Collected fractions were precipitated by the method described by Wessel & Flügge (Wessel and Flugge, 1984) . To compare different samples, pellets were resuspended in normalized volumes of sample buffer according to the determined fluorescence signal. Binding efficiency was determined by Western Blot analysis using the Fusion Capt advance software, comparing band intensities of start materials with collected fractions.
Generation of GUVs and analysis Detergent solubilized EGFP-ycBD-BC08 and EGFP-RanBD-BC08 were reconstituted in proteo-liposomes via gelfiltration (Eisenhardt et al., 2014) . For this, 20 µl of the NE lipid mix without NBD-PE (30 mg/ml in 10% octylglucopyranoside) was mixed with 20 µl of 2 µM protein and 100 µl PBS. The sample was applied to a Sephadex G50 fine filled Econo chromatography column (0.5 × 20 cm, Biorad) to remove the detergent. The formed proteo-liposomes were collected and pelleted for 30 min at 100.000 rpm in a TLA120.2 (Beckman Coulter) rotor at 4°C. The pellet was resuspended in 120 µl 20 mM HEPES pH 7.4, 100 mM KCl, 1 mM DTT. 5 µl of resuspended proteoliposomes were dried onto two 5 mm x 5 mm platinum gauzes (ALS) under vacuum for at least 1 h at room temperature. The gauzes were placed in parallel (5 mm distance) into a cuvette (UVette, Eppendorf) and submerged in 259 mM sucrose solution and for 140 min an AC electric field with 10 Hz, 2.2 V was applied followed by 20 min 2 Hz at 42°C. Lipid GUVs were generated from chloroform dissolved NE lipid mix (10 mg/ml) and 0.8 nM DiDC18 by electroformation as described (Angelova and Dimitrov, 1986) . Equal amounts of the lipid-chloroform solution (25 µg total lipids) were distributed onto two 5 mm x 5 mm platinum gauzes (ALS) and processed as described before. Electroformation time at 10 Hz was reduced to 70 min. GUVs were visualized in an 8 well glass observation chamber (Chambered #1.0 Borosilicate Coverglass System, Lab-Tek) that was blocked with 5 % (wt/vol) BSA in PBS and washed with PBS. For each reaction 50 µl of freshly prepared GUVs were mixed with 150 µl PBS and placed into a well. Soluble proteins were added to a final concentration of 500 nM. Proteins (25 nM for the purified labelled y-complex) and buffers used for GUV preparation matched the osmotic pressure of the sucrose solution using an osmometer. The mixture was incubated for 5 min and imaged immediately at room temperature on an inverted Olympus Fluoview 1000 confocal laser scanning system utilizing an UPlanSApo 60x/1.35 oil objective. EGFP and Alexa-546 were excited by an argon ion laser at 488 nm and 515 nm. Emission for EGFP was collected between 500 to 545 nm and between 570 to 625 nm for Alexa-546. DiD was excited by a 635 nm DPSS laser and emission was collected between 655 to 755 nm. The pinhole was set to one airy unit.
Dextran exclusion assay to monitor interphasic NPC formation Nuclei were assembled by incubating 0.3 µl demembranted sperm heads (10.000/µl) (Gurdon, 1976 ) with 10 µl mock or depleted cytosol and, where indicated, recombinant proteins or proteo-liposomes. After 10 min, which allows for decondensation of sperm DNA, 0.2 µl floatation purified membranes from egg extracts, 0.2 µl 200 µg/µl glycogen, and 0.2 µl energy mix (50 mM ATP, 50 mM GTP, 500 mM creatine phosphate and 10 mg/ml creatine kinase in sucrose buffer [10 mM HEPES, 250 mM sucrose, 50 mM KCl, 2.5 mM MgCl 2 , pH 7.4]) was added. After additional 40 min, 20 µl of mock or Nup153 depleted extracts, which had been incubated for 20 min with 30 µl WGA-Agarose (Sigma) to remove the permeability barrier forming nucleoporins, were added. Where indicated 2 µM importin β was added to inhibit further interphasic NPC assembly together with the WGA-treated extracts. After additional 50 min, 0.6 µl of a solution containing 5 µg/µl streptavidin and 5 µg/µl biotinylated WGA (both from Life Technologies) was added in order to reduce the diffusion of 70kDa dextrans through intact pores (Dawson). After 10 min, 2.5 µl of a mixture containing 0.25 µg/µl Alexa-488 labelled WGA (Life Technologies) and 0.25 µg/µl Hoechst in sucrose buffer was added. Samples were directly mounted on microscope slides and analysed by fluorescence microscopy. Nuclei, identified by Hoechst staining, that excluded the fluorescent dextran were counted as negative for interphasic NPC assembly.
NPC counting using mAB414 labeling Nuclei were assembled by incubating 0.3 µl demembranted sperm heads (10.000/µl) with 10 µl mock or depleted cytosol and, where indicated, recombinant proteins or proteo-liposomes. After 10 min, which allows for decondensation of sperm DNA, 0.2 µl floatation purified membranes from egg extracts, 0.2 µl 200 µg/µl glycogen, and 0.2 µl energy mix (50 mM ATP, 50 mM GTP, 500 mM creatine phosphate and 10 mg/ml creatine kinase in sucrose buffer) was added. After assembly for 120 min, samples were fixed with 4 % paraformaldehyde and 0,5% glutaraldehyde in 80 mM Pipes pH 6.8, 1 mM MgCl 2 , 150 mM sucrose, spun through a sucrose cushion on Poly-L-Lysine coated coverslips and stained with mAB414 and Alexa-488 labelled α-mouse antibodies and DAPI. Where indicated, further interphasic NPC assembly was inhibited by addition of 2 µM importin β 50 min after initiating the assembly reaction. Although postmitotic NPC assembly is in the assembly reaction usually completed after 30 min (i.e. the time when a closed nuclear envelope has formed, 20 min after addition of membranes) we add also in this assay importin β at the 50 min time point to ensure that only interphasic NPC assembly is affected. The NPCs from 30 -50 nuclei in each independent experiment were imaged by acquiring stacked images of the envelope surface as well as through entire nuclei. Image recording was performed using an inverted Olympus Fluoview 1000 confocal laser scanning system utilizing an UPlanSApo 60x/1.35 oil objective. DAPI was excited by a 405 nm DPSS laser and emission was collected between 425 to 475 nm. Alexa-488 was excited by an argon ion laser at 488 nm and emission was collected between 500 to 545 nm. The pinhole size was set to 80 µm.
